NCT00710372

Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 83 (actual)
• Sponsor: Cytos Biotechnology AG · Industry
• Sex: All
• Age: 18 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

The study medication CYT006-AngQb is a vaccine, consisting of angiotensin II (Ang II), the naturally occurring octapeptide coupled onto the surface of virus-like particles (VLP). This form of presenting Ang II to the immune system induces a B-cell mediated immune response characterized by the generation of specific antibodies (IgG and IgM) against Ang II. The CYT006-AngQb vaccine is administered by subcutaneous (s.c.) injection. Immunization against angiotensin II may offer a valuable alternative to conventional drugs for the treatment of hypertension.

Conditions

• Mild Essential Hypertension
• Moderate Essential Hypertension

Interventions

Type	Name	Description
BIOLOGICAL	CYT006-AngQb	s.c. injection

Timeline

• Start date: 2008-06-01
• Primary completion: 2009-07-01
• Completion: 2010-11-01
• First posted: 2008-07-04
• Last updated: 2010-11-15

Locations

1 site across 1 country: Switzerland